361 related articles for article (PubMed ID: 29061774)
21. Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression.
Howitt BE; Strickland KC; Sholl LM; Rodig S; Ritterhouse LL; Chowdhury D; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncoimmunology; 2017; 6(2):e1277308. PubMed ID: 28344892
[TBL] [Abstract][Full Text] [Related]
22. Immuno-Oncology for Gynecologic Malignancies.
How JA; Patel A; Jazaeri AA
Adv Exp Med Biol; 2021; 1342():193-232. PubMed ID: 34972966
[TBL] [Abstract][Full Text] [Related]
23. Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies.
Ring KL; Pakish J; Jazaeri AA
Cancer J; 2016; 22(2):101-7. PubMed ID: 27111905
[TBL] [Abstract][Full Text] [Related]
24. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer.
Post CCB; Westermann AM; Bosse T; Creutzberg CL; Kroep JR
Crit Rev Oncol Hematol; 2020 Aug; 152():102973. PubMed ID: 32497971
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
[TBL] [Abstract][Full Text] [Related]
26. Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity.
Mittica G; Ghisoni E; Giannone G; Aglietta M; Genta S; Valabrega G
Oncotarget; 2017 Oct; 8(52):90532-90544. PubMed ID: 29163851
[TBL] [Abstract][Full Text] [Related]
27. Targeting the programmed cell death-1 pathway in breast and ovarian cancer.
Emens LA; Kok M; Ojalvo LS
Curr Opin Obstet Gynecol; 2016 Apr; 28(2):142-7. PubMed ID: 26881392
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy of gynecological cancers.
Matanes E; Gotlieb WH
Best Pract Res Clin Obstet Gynaecol; 2019 Oct; 60():97-110. PubMed ID: 31003902
[TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.
Menderes G; Hicks C; Black JD; Schwab CL; Santin AD
Expert Opin Biol Ther; 2016 Aug; 16(8):989-1004. PubMed ID: 27070175
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.
Ventriglia J; Paciolla I; Pisano C; Cecere SC; Di Napoli M; Tambaro R; Califano D; Losito S; Scognamiglio G; Setola SV; Arenare L; Pignata S; Della Pepa C
Cancer Treat Rev; 2017 Sep; 59():109-116. PubMed ID: 28800469
[TBL] [Abstract][Full Text] [Related]
31. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.
Gatalica Z; Snyder C; Maney T; Ghazalpour A; Holterman DA; Xiao N; Overberg P; Rose I; Basu GD; Vranic S; Lynch HT; Von Hoff DD; Hamid O
Cancer Epidemiol Biomarkers Prev; 2014 Dec; 23(12):2965-70. PubMed ID: 25392179
[TBL] [Abstract][Full Text] [Related]
32. PD-1 and PD-L1 blockade in gastrointestinal malignancies.
Lote H; Cafferkey C; Chau I
Cancer Treat Rev; 2015 Dec; 41(10):893-903. PubMed ID: 26412280
[TBL] [Abstract][Full Text] [Related]
33. The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies.
Marinelli O; Annibali D; Aguzzi C; Tuyaerts S; Amant F; Morelli MB; Santoni G; Amantini C; Maggi F; Nabissi M
Front Oncol; 2019; 9():1073. PubMed ID: 31681606
[TBL] [Abstract][Full Text] [Related]
34. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
35. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
Higuchi T; Flies DB; Marjon NA; Mantia-Smaldone G; Ronner L; Gimotty PA; Adams SF
Cancer Immunol Res; 2015 Nov; 3(11):1257-68. PubMed ID: 26138335
[TBL] [Abstract][Full Text] [Related]
36. Major clinical research advances in gynecologic cancer in 2021.
Park JY; Lee JY; Lee YY; Shim SH; Suh DH; Kim JW
J Gynecol Oncol; 2022 Mar; 33(2):e43. PubMed ID: 35245004
[TBL] [Abstract][Full Text] [Related]
37. Immune checkpoint inhibitors for recurrent endometrial cancer.
Mutlu L; Harold J; Tymon-Rosario J; Santin AD
Expert Rev Anticancer Ther; 2022 Mar; 22(3):249-258. PubMed ID: 35176955
[TBL] [Abstract][Full Text] [Related]
38. Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?
Taha T; Reiss A; Amit A; Perets R
BioDrugs; 2020 Dec; 34(6):749-762. PubMed ID: 33141420
[TBL] [Abstract][Full Text] [Related]
39. Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.
Diaz-Padilla I; Duran I; Clarke BA; Oza AM
Cancer Treat Rev; 2012 Oct; 38(6):767-75. PubMed ID: 22381585
[TBL] [Abstract][Full Text] [Related]
40. PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer.
Saglam O; Conejo-Garcia J
Integr Cancer Sci Ther; 2018; 5(2):. PubMed ID: 29955379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
